Breaking News, Financial News

Novartis 4Q Results

Revenue growth in the quarter driven by Entresto, Kesimpta, Kisqali, Cosentyx, and Leqvio, offset by declines for Lucentis and Gilenya.

Image: Novartis

Novartis

4Q Revenues: $13.2 billion (+15%)

4Q Earnings: $2.8 billion (-67%)

FY Revenues: $50.3 billion (+11%)

FY Earnings: $11.9 billion (-24%)

Comments: Sales growth in the quarter was mainly driven by Entresto with $2.2 billion in sales, up 33%, Kesimpta sales of $950 million, up 48%, Kisqali sales of $902 million, up 48%, Cosentyx sales of $1.6 billion, up 22%, and Leqvio sales of $223 million, up 81%, partly offset by declines mainly for Lucentis, with sales down 30% to $210 million, and Gilenya down 29% to $109 million, due to generic competition.

Earnings reflect R&D investments in 2024 including the acquisition of Kate Therapeutics, Mariana Oncology, IFM Due, MorphoSys AG, Calypso Biotech BV, and SanReno Therapeutics. Additionally, as the Sandoz spin-off was completed on October 2023, there were no operating results in 2024 related to discontinued operations.

Read more about Novartis’ acquisitions in 2024 here.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters